Clinical characteristics and their correlation with clinical subtypes and survival in 50 cases of adult T-cell leukemia/lymphoma
| Characteristic . | Acute (n = 37) . | Lymphoma (n = 6) . | Chronic (n = 7) . | Total (n = 50) . | Acute vs lymphoma . | Acute and lymphoma vs chronic . | Survival . | |
|---|---|---|---|---|---|---|---|---|
| ≥ 6 (n = 34)/ < 6 (n = 16) mo . | Overall . | |||||||
| Sex | ||||||||
| Male | 24 (64.9%) | 5 (83.3%) | 3 (42.9%) | 32 (64.0%) | NS | NS | NS | NS |
| Male/female ratio | 1.8 | 5 | 0.8 | 1.8 | ||||
| Age, y | ||||||||
| Median | 59 | 59 | 55 | 59 | ||||
| Range | 33-81 | 52-71 | 32-75 | 32-81 | ||||
| ≥ 50 | 30 (81.1%) | 6 (100%) | 4 (57.1%) | 40 (80%) | NS | NS | NS | NS |
| Skin lesion | 16 (43.2%) | 1 (16.7%) | 1 (14.3%) | 18 (36.0%) | NS | NS | NS | NS |
| Peripheral lymphadenopathy | 26 (70.3%) | 5 (83.3%) | 2 (28.6%) | 33 (66.0%) | NS | P < .05*,† | NS | NS |
| Hepatosplenomegaly | 21 (56.6%) | 3 (50.0%) | 2 (28.6%) | 26 (52.0%) | NS | NS | NS | P < .05‡ |
| CNS involvement | 5 (13.5%) | 1 (16.7%) | 0 | 6 (12.0%) | NS | NS | NS | P < .05‡ |
| Pleural effusion and/or ascites | 7 (18.9%) | 0 | 0 | 7 (14.0%) | NS | NS | NS | NS |
| Serum LDH, IU/μL | ||||||||
| Median | 1257 | 1479 | 324 | 1166.5 | ||||
| Range | 497-9517 | 820-2660 | 236-554 | 236-9517 | ||||
| ≥ 1100 | 23 (62.2%) | 4 (66.7%) | 0 | 27 (54.0%) | NS | P < .01*,† | P < .05†,1-153 | P < .01‡ |
| Hypercalcemia | 24 (48%) | 3 (50%) | 0 | 27 (54.0%) | NS | P < .01*,† | P < .05†,1-153 | P < .01‡ |
| WBC, ×106/L | ||||||||
| Median | 24.0 | 5.6 | 11.4 | 21.3 | ||||
| Range | 2.8-215.4 | 2.8-40.0 | 5.5-108.4 | 2.8-215.4 | ||||
| ≥ 30.0 | 18 (48.6%) | 1 (16.7%) | 1 (14.3%) | 20 (40.0%) | NS | NS | NS | NS |
| Absolute abnormal lymphocyte count, ×106/L | ||||||||
| Median | 11.2 | 0 | 2.1 | 7.2 | ||||
| Range | 1.3-114.2 | 0 | 0-9.2 | 0-114.2 | ||||
| ≥ 15.0 | 15 (40.5%) | 0 | 1 (14.3%) | 16 (32.0%) | NS | NS | NS | NS |
| Unusual immunophenotype | 7 (18.9%) | 1 (16.7%) | 0 | 8 (16.0%) | NS | NS | NS | P < .01‡ |
| Survival, mo | ||||||||
| Median | 8.0 | 14.0 | 59.0 | 10.05 | ||||
| Range | 0.2-71.0 | 0.6-20.0 | 12.0-148.0 | 0.2-148.0 | ||||
| < 6 | 14 (37.8%) | 2 (33.3%) | 0 | 16 (32.0%) | NS | NS | ||
| Overall | NS | P < .01‡ | ||||||
| Characteristic . | Acute (n = 37) . | Lymphoma (n = 6) . | Chronic (n = 7) . | Total (n = 50) . | Acute vs lymphoma . | Acute and lymphoma vs chronic . | Survival . | |
|---|---|---|---|---|---|---|---|---|
| ≥ 6 (n = 34)/ < 6 (n = 16) mo . | Overall . | |||||||
| Sex | ||||||||
| Male | 24 (64.9%) | 5 (83.3%) | 3 (42.9%) | 32 (64.0%) | NS | NS | NS | NS |
| Male/female ratio | 1.8 | 5 | 0.8 | 1.8 | ||||
| Age, y | ||||||||
| Median | 59 | 59 | 55 | 59 | ||||
| Range | 33-81 | 52-71 | 32-75 | 32-81 | ||||
| ≥ 50 | 30 (81.1%) | 6 (100%) | 4 (57.1%) | 40 (80%) | NS | NS | NS | NS |
| Skin lesion | 16 (43.2%) | 1 (16.7%) | 1 (14.3%) | 18 (36.0%) | NS | NS | NS | NS |
| Peripheral lymphadenopathy | 26 (70.3%) | 5 (83.3%) | 2 (28.6%) | 33 (66.0%) | NS | P < .05*,† | NS | NS |
| Hepatosplenomegaly | 21 (56.6%) | 3 (50.0%) | 2 (28.6%) | 26 (52.0%) | NS | NS | NS | P < .05‡ |
| CNS involvement | 5 (13.5%) | 1 (16.7%) | 0 | 6 (12.0%) | NS | NS | NS | P < .05‡ |
| Pleural effusion and/or ascites | 7 (18.9%) | 0 | 0 | 7 (14.0%) | NS | NS | NS | NS |
| Serum LDH, IU/μL | ||||||||
| Median | 1257 | 1479 | 324 | 1166.5 | ||||
| Range | 497-9517 | 820-2660 | 236-554 | 236-9517 | ||||
| ≥ 1100 | 23 (62.2%) | 4 (66.7%) | 0 | 27 (54.0%) | NS | P < .01*,† | P < .05†,1-153 | P < .01‡ |
| Hypercalcemia | 24 (48%) | 3 (50%) | 0 | 27 (54.0%) | NS | P < .01*,† | P < .05†,1-153 | P < .01‡ |
| WBC, ×106/L | ||||||||
| Median | 24.0 | 5.6 | 11.4 | 21.3 | ||||
| Range | 2.8-215.4 | 2.8-40.0 | 5.5-108.4 | 2.8-215.4 | ||||
| ≥ 30.0 | 18 (48.6%) | 1 (16.7%) | 1 (14.3%) | 20 (40.0%) | NS | NS | NS | NS |
| Absolute abnormal lymphocyte count, ×106/L | ||||||||
| Median | 11.2 | 0 | 2.1 | 7.2 | ||||
| Range | 1.3-114.2 | 0 | 0-9.2 | 0-114.2 | ||||
| ≥ 15.0 | 15 (40.5%) | 0 | 1 (14.3%) | 16 (32.0%) | NS | NS | NS | NS |
| Unusual immunophenotype | 7 (18.9%) | 1 (16.7%) | 0 | 8 (16.0%) | NS | NS | NS | P < .01‡ |
| Survival, mo | ||||||||
| Median | 8.0 | 14.0 | 59.0 | 10.05 | ||||
| Range | 0.2-71.0 | 0.6-20.0 | 12.0-148.0 | 0.2-148.0 | ||||
| < 6 | 14 (37.8%) | 2 (33.3%) | 0 | 16 (32.0%) | NS | NS | ||
| Overall | NS | P < .01‡ | ||||||